Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SLDB stock, giving a Buy rating on July 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight Solid Biosciences’ promising advancements in gene therapy. The company has received regulatory clearance for SGT-501, a gene therapy targeting catecholaminergic polymorphic ventricular tachycardia (CPVT), marking a significant milestone as they prepare to initiate clinical trials. This progress is notable considering the company’s transition from preclinical stages just two years ago to having three drugs in the clinic.
Solid Biosciences’ SGT-501 utilizes AAV8 to deliver a functional copy of the CASQ2 gene, aiming to stabilize RYR2 and reduce pathological ventricular tachycardia. Preclinical data suggests that SGT-501 can effectively prevent arrhythmias in mouse models, indicating potential efficacy in human trials. The upcoming Phase 1b study will focus on evaluating the safety and initial efficacy of SGT-501, with the ultimate goal of providing durable protection against arrhythmias and reducing reliance on current medications. These developments, along with the company’s strategic focus on cardiac gene therapy, underpin Schwartz’s optimistic outlook for Solid Biosciences.
SLDB’s price has also changed moderately for the past six months – from $4.030 to $5.240, which is a 30.02% increase.